← Eichor
Study identifier: NCT07076498 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Engineered HSV-1 M032 for the Treatment of Children and Adults With Newly Diagnosed Diffuse Midline Glioma After Standard of Care Radiation

Condition: Glioma  ·  Sponsor: M.D. Anderson Cancer Center

PhasePhase 1
Planned participants20
Who can joinAll sexes, 36 Months to no upper limit
Healthy volunteersNo

About this study

The goal of this clinical research study is to learn about the safety and effects of M032 given directly into the tumor in children and adults with DMG and who have received standard-of-care radiation therapy.

This description comes directly from the study's public registry record.

Talk to the study team

Gregory Friedman, MD  ·  713-835-4467  ·  gkfriedman@mdanderson.org

Kara Kachurak, PNP  ·  713-835-4467  ·  kgkachurak@mdanderson.org

Always discuss trial participation with your own doctor first.

Locations (1)

The University of Texas M. D. Anderson Cancer CenterHouston, Texas, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07076498